Story Stocks^®

Gilead Sciences (GILD) is expanding its oncology and cell therapy footprint through a definitive agreement to acquire Arcellx (ACLX), deepening a collaboration that began several years ago. The transaction gives GILD full strategic control over a promising late-stage CAR-T program in multiple myeloma and strengthens its long-term position in hematologic malignancies. Management views the deal as a way to streamline development, capture full economics, and build on its growing cell therapy platform.

• GILD is paying $115/share in cash plus a $5 contingent value right (CVR) tied to cumulative global net sales of anito-cel reaching at least $6 bln by the end of 2029. The total implied equity value of the transaction is $7.8 bln.
• ACLX is a clinical-stage biotech and existing partner. GILD previously held an 11.5% equity stake.
• Lead asset anito-cel is a BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma, demonstrating deep and durable responses in clinical trials, including high overall response rates and strong complete response rates with a favorable safety profile.
• Anito-cel is positioned to compete with Johnson & Johnson's (JNJ) Carvykti, with differentiation centered on its D-Domain binder designed to optimize binding and potentially reduce toxicity such as CRS and neurotoxicity.
• Regulatory submissions are anticipated in the next couple of years, with potential approvals later this decade. The global multiple myeloma market represents a multi-billion-dollar opportunity, particularly as CAR-T moves earlier in treatment lines.
• GILD also gains full ownership of ACLX’s D-Domain platform, which can be leveraged for next-generation CAR-T and in vivo cell therapy programs.
• GILD expects the transaction to be accretive to EPS beginning in 2028 and thereafter.

Briefing.com Analyst Insight

Strategically, ACLX fits squarely within GILD’s ambition to build a leadership position in oncology and cell therapy, complementing its existing hematology portfolio and commercial infrastructure. Full ownership of anito-cel eliminates profit-sharing and governance complexity, while giving GILD greater flexibility to accelerate development, pursue label expansions, and optimize global commercialization. In multiple myeloma -- a market that continues to expand as patients live longer and cycle through multiple lines of therapy -- CAR-T remains one of the most effective options for relapsed or refractory disease, supporting a sizable and growing total addressable market. If anito-cel can demonstrate comparable efficacy to Carvykti with a differentiated safety or durability profile, it could capture meaningful share in a high-value segment. Beyond the lead asset, the D-Domain platform adds long-term optionality in engineered cell therapies, potentially extending GILD’s pipeline into next-generation and in vivo approaches. With expected EPS accretion beginning in 2028, the deal appears structured to balance near-term capital deployment with long-term strategic and financial upside.